Clinical characteristics of survivors with and without live birth after BMT
| Variables of interest . | Post-BMT live birth . | P value . | |
|---|---|---|---|
| Yes n = 120, (%) . | No n = 1255, (%) . | ||
| Sex | |||
| Female | 52 (43.3) | 589 (46.9) | .5 |
| Age at BMT in years | |||
| <11 | 12 (10.0) | 103 (8.2) | <.0001* |
| 12-24 | 44 (36.7) | 279 (22.2) | |
| 25-34 | 50 (41.7) | 338 (27.0) | |
| >35 | 14 (11.7) | 535 (42.6) | |
| Follow-up since BMT in years | |||
| Median (IQR) | 16.4 (4.3-39.9) | 14.1 (2.4-41.4) | .005* |
| Age at survey in years | |||
| Median (IQR) | 42 (23-66) | 47 (18-73) | .0004* |
| Race\ethnicity | |||
| Non-Hispanic White | 91 (75.8) | 903 (72.1) | .5 |
| Hispanic | 18 (15.0) | 189 (15.1) | |
| Other† | 11 (9.2) | 161 (12.9) | |
| BMT type | |||
| Autologous BMT | 49 (40.8) | 492 (39.2) | .7 |
| Diagnosis | |||
| HL/NHL | 49 (40.8) | 400 (31.9) | <.0001* |
| ALL/AML/MDS | 25 (20.8) | 479 (38.2) | |
| SAA | 23 (19.2) | 70 (5.58) | |
| Other‡ | 23 (19.2) | 306 (24.4) | |
| Conditioning regimen | |||
| TBI | 45 (37.5) | 740 (58.9) | <.0001* |
| Cyclophosphamide | 92 (76.7) | 814 (64.9) | .01* |
| Nitrosoureas | 21 (17.5) | 130 (10.4) | .02* |
| Etoposide | 42 (35.0) | 501 (39.9) | .3 |
| Busulfan | 22 (18.3) | 162 (12.9) | .1 |
| Cytarabine | 2 (1.7) | 37 (2.9) | .4 |
| Melphalan | 5 (4.2) | 99 (7.9) | .1 |
| Fludarabine | 11 (9.2) | 154 (12.3) | .3 |
| Conditioning intensity | |||
| Low-intensity conditioning | 27 (24.8) | 185 (16.7) | .03* |
| High-intensity conditioning | 82 (75.2) | 923 (83.3) | |
| Total Body Irradiation dose, cGy/Condition intensity§ | |||
| No TBI/low-intensity conditioning | 19 (17.8) | 124 (11.5) | <.0001* |
| 200-800 cGy TBI/low-intensity conditioning | 8 (7.4) | 56 (5.2) | |
| No TBI/high-intensity conditioning | 45 (42.1) | 245 (22.8) | |
| >800 cGy TBI/high-intensity conditioning | 35 (32.7) | 650 (60.5) | |
| cGVHDǁ | |||
| Yes | 29 (43.3) | 371 (50.5) | .3 |
| Chronic health conditions | |||
| Grade 3 or 4 | 36 (30.8) | 472 (39.2) | .07 |
| Educational status | |||
| >high school education | 101 (84.2) | 1062 (84.9) | .8 |
| Availability of current health insurance | |||
| Health insurance available | 110 (91.7) | 1209 (96.3) | .01* |
| Annual household income | |||
| <$50 000 | 30 (25.0) | 362 (28.8) | .001* |
| $50 000-$100 000 | 29 (24.2) | 358 (28.5) | |
| >$100 000 | 55 (45.8) | 370 (29.5) | |
| Not available | 6 (5.0) | 165 (13.2) | |
| History of pre-BMT livebirth | |||
| Yes | 21 (17.5) | 474 (37.8) | <.0001* |
| Tried medical intervention to become pregnant | |||
| Yes¶ | 53 (44.2) | 254 (20.2) | <.0001* |
| Disease status at first BMT | |||
| High risk | 35 (39.8) | 454 (42.5) | .6 |
| History of pre-BMT pelvic/testicular radiation | |||
| Yes | 1 (0.8) | 25 (1.2) | .3 |
| Pre-BMT alkylating agents | |||
| Yes | 58 (48.3) | 558 (44.5) | .4 |
| Variables of interest . | Post-BMT live birth . | P value . | |
|---|---|---|---|
| Yes n = 120, (%) . | No n = 1255, (%) . | ||
| Sex | |||
| Female | 52 (43.3) | 589 (46.9) | .5 |
| Age at BMT in years | |||
| <11 | 12 (10.0) | 103 (8.2) | <.0001* |
| 12-24 | 44 (36.7) | 279 (22.2) | |
| 25-34 | 50 (41.7) | 338 (27.0) | |
| >35 | 14 (11.7) | 535 (42.6) | |
| Follow-up since BMT in years | |||
| Median (IQR) | 16.4 (4.3-39.9) | 14.1 (2.4-41.4) | .005* |
| Age at survey in years | |||
| Median (IQR) | 42 (23-66) | 47 (18-73) | .0004* |
| Race\ethnicity | |||
| Non-Hispanic White | 91 (75.8) | 903 (72.1) | .5 |
| Hispanic | 18 (15.0) | 189 (15.1) | |
| Other† | 11 (9.2) | 161 (12.9) | |
| BMT type | |||
| Autologous BMT | 49 (40.8) | 492 (39.2) | .7 |
| Diagnosis | |||
| HL/NHL | 49 (40.8) | 400 (31.9) | <.0001* |
| ALL/AML/MDS | 25 (20.8) | 479 (38.2) | |
| SAA | 23 (19.2) | 70 (5.58) | |
| Other‡ | 23 (19.2) | 306 (24.4) | |
| Conditioning regimen | |||
| TBI | 45 (37.5) | 740 (58.9) | <.0001* |
| Cyclophosphamide | 92 (76.7) | 814 (64.9) | .01* |
| Nitrosoureas | 21 (17.5) | 130 (10.4) | .02* |
| Etoposide | 42 (35.0) | 501 (39.9) | .3 |
| Busulfan | 22 (18.3) | 162 (12.9) | .1 |
| Cytarabine | 2 (1.7) | 37 (2.9) | .4 |
| Melphalan | 5 (4.2) | 99 (7.9) | .1 |
| Fludarabine | 11 (9.2) | 154 (12.3) | .3 |
| Conditioning intensity | |||
| Low-intensity conditioning | 27 (24.8) | 185 (16.7) | .03* |
| High-intensity conditioning | 82 (75.2) | 923 (83.3) | |
| Total Body Irradiation dose, cGy/Condition intensity§ | |||
| No TBI/low-intensity conditioning | 19 (17.8) | 124 (11.5) | <.0001* |
| 200-800 cGy TBI/low-intensity conditioning | 8 (7.4) | 56 (5.2) | |
| No TBI/high-intensity conditioning | 45 (42.1) | 245 (22.8) | |
| >800 cGy TBI/high-intensity conditioning | 35 (32.7) | 650 (60.5) | |
| cGVHDǁ | |||
| Yes | 29 (43.3) | 371 (50.5) | .3 |
| Chronic health conditions | |||
| Grade 3 or 4 | 36 (30.8) | 472 (39.2) | .07 |
| Educational status | |||
| >high school education | 101 (84.2) | 1062 (84.9) | .8 |
| Availability of current health insurance | |||
| Health insurance available | 110 (91.7) | 1209 (96.3) | .01* |
| Annual household income | |||
| <$50 000 | 30 (25.0) | 362 (28.8) | .001* |
| $50 000-$100 000 | 29 (24.2) | 358 (28.5) | |
| >$100 000 | 55 (45.8) | 370 (29.5) | |
| Not available | 6 (5.0) | 165 (13.2) | |
| History of pre-BMT livebirth | |||
| Yes | 21 (17.5) | 474 (37.8) | <.0001* |
| Tried medical intervention to become pregnant | |||
| Yes¶ | 53 (44.2) | 254 (20.2) | <.0001* |
| Disease status at first BMT | |||
| High risk | 35 (39.8) | 454 (42.5) | .6 |
| History of pre-BMT pelvic/testicular radiation | |||
| Yes | 1 (0.8) | 25 (1.2) | .3 |
| Pre-BMT alkylating agents | |||
| Yes | 58 (48.3) | 558 (44.5) | .4 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HL, Hodgkin's lymphoma; MDS, myelodysplastic syndromes; NHL, non-Hodgkin's lymphoma; SAA, severe aplastic anemia; TBI, total body irradiation.
Statistically significant differences between groups.
Other race included: Asian, African American, American Indian, multiracial, and Pacific Islander.
Other diagnosis included: chronic myeloid leukemia, other leukemia, paraneoplastic cerebellar degeneration, dyskeratosis congenita, germ cell tumor, extragonadal, inherited abnormality of erythrocyte differentiation and/or function, medulloblastoma, metachromatic leukodystrophy, MS, PNET, rhabdomyosarcoma, sickle cell disease, scleroderma, and testicular carcinoma.
High-intensity conditioning = myeloablative intensity conditioning; low-intensity conditioning = nonmyeloablative/reduced-intensity conditioning.
cGVHD among patients who received allogeneic transplantation.
Participants who sought fertility assistance by consulting a doctor or taking fertility-promoting medications.